In a significant development for the pharmaceutical sector in Uzbekistan, the representative of the renowned Italian pharmaceutical company, IBSA Group, engaged in discussions with key stakeholders at the Agency for the Development of the Pharmaceutical Network. The meeting presided over by Abdulla Azizov, former business development manager of IBSA Group and a prominent member of the Council of the Italian-Uzbekistan Chamber of Commerce, explored potential avenues for collaboration and investment.
During the introductory session, the director of the Agency provided insights into the institution's role in fostering pharmaceutical development within Uzbekistan. Expressing a keen interest in the country's pharmaceutical landscape, the Italian company was encouraged to consider implementing its investment projects, with assurances of support from the Agency.
Marco Farchi, the former business development manager of IBSA Group, brought a unique proposal to the table. Leveraging his role as a member of the Council of Italian companies in Uzbekistan, Farchi proposed establishing collaborations with other promising Italian pharmaceutical firms. Notably, companies such as A. Menarini Industrie Farmaceutiche Riunite SRL, Italfarmaco SpA, Chemi SpA, Chiesi Farmaceutici, among others, were highlighted as potential partners for future initiatives.
Farchi, who also has ties to the academic sphere, has played a pivotal role in organizing academic collaborations between Italy and Uzbekistan. Specifically, he has introduced student exchange programs and practices aimed at enhancing the skills and knowledge of pharmacists within the country.
In light of Farchi's extensive network and influence within the Italian pharmaceutical sector, practical assistance was sought to establish contact with these companies and initiate discussions regarding potential localization initiatives. The aim is to create a conducive environment for collaboration that aligns with the development goals of both nations.
For those unfamiliar with IBSA Group, it is a Swiss multinational pharmaceutical company with a rich history dating back to its founding in 1945 in Lugano. Operating in more than 90 countries, IBSA has emerged as one of the world's largest reproductive health operators, offering a diverse portfolio of products covering ten therapeutic groups.
The company specializes in reproductive medicine, endocrinology, pain and inflammation, bone and joints, aesthetic medicine, dermatology, urogynecology, cardiometabolic, and respiratory medicine. With 18 subsidiaries across Europe, China, and the USA, IBSA is renowned for its expertise in producing products based on hyaluronic acid.
These deliberations unfold just hours prior to the official reception of the President of the Italian Republic, Sergio Mattarella, at the Tashkent International Airport, where he is warmly greeted by the Prime Minister of the Republic of Uzbekistan, Abdulla Aripov, alongside other distinguished guests. This significant visit is poised to facilitate profound discussions at the highest echelons, dedicated to advancing the strategic partnership between Uzbekistan and Italy. The focal point of these conversations lies in the augmentation of mutually advantageous collaboration across pivotal sectors.
Follow Daryo's official Instagram and Twitter pages to keep current on world news.
Comments (0)